SCHEMBL31412684

SCHEMBL31412684

Cc1c(-c2ccnnc2)n[nH]c1C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 1/20 0.48
▸ HCAR2 Q8TDS4 1/20 0.41
▸ MAPT P10636 3/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ LRRK2 Q5S007 1/20 0.39
▸ MAPK1 P28482 1/20 0.38
▸ MAP2K4 P45985 1/20 0.38
▸ MAPKAPK3 Q16644 1/20 0.38
▸ MAPK6 Q16659 1/20 0.38
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ LMNA P02545 1/20 0.37
▸ PKM P14618 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ GPR35 Q9HC97 1/20 0.36
▸ HDAC6 Q9UBN7 1/20 0.36
▸ WNT3A P56704 2/20 0.35
▸ KDM4E B2RXH2 3/20 0.34
▸ ALPL P05186 3/20 0.34
▸ HSD17B10 Q99714 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31412631 0.81 HCAR2 (0.41) RAB9AHCAR2ALDH1A1LRRK2MAPK1
SCHEMBL6822516 0.80 RAB9A (0.69) RAB9AMAPTALDH1A1MAPK1MAP2K4
SCHEMBL5317383 0.76 HDAC6 (0.56) RAB9AMAPTALDH1A1MAPK1MAP2K4
SCHEMBL16116177 0.73 CCNC (0.55) HCAR2GPR35WNT3AHDAC4
SCHEMBL5937211 0.73 RAB9A (0.49) RAB9AMAPTALDH1A1MAPK1MAP2K4
SCHEMBL31412648 0.73 KDM4C (0.38) RAB9AMAPTALDH1A1LRRK2MAPK1
SCHEMBL11071707 0.72 RAB9A (0.51) RAB9AMAPTALDH1A1MAPK1MAP2K4
SCHEMBL6821694 0.69 RAB9A (0.44) RAB9AHCAR2MAPTALDH1A1MAP2K4
SCHEMBL31412652 0.68 TP53 (0.65) SMN1; SMN2KDM4EALPL
SCHEMBL4638325 0.68 RAB9A (0.70) RAB9AMAPTALDH1A1MAPK1MAP2K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025045746-A1 PYRAZOLE DERIVATIVES AS SARM1 INHIBITORS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2025-03-06 — — WO disclosed
Send feedback